Broad-Spectrum DNA Therapeutics

Unmet Need

Many current and emerging antiviral drugs have chemical characteristics that result in poor cell penetration, which limits their ability to reach their intended target. These therapeutics cannot be given orally and must be delivered at high concentrations. The result is potential toxicity issues that limit their widespread use.


TSRL, Inc. is developing novel antiviral analogues of proven therapeutics against a broad range of viral infections. Our pre-lead candidates are prodrugs of cidofovir and closely related nucleoside phosphonate analogues. They are orally available with substantially increased cell-based potency against ganciclovir resistant human cytomegalovirus (hCMV) and a broad range of adenovirus strains, herpes viruses, polyoma viruses and smallpox.

Research Status

We are in the process of identifying a lead-candidate from the current set of preleads based on maximal broad-spectrum in vivo efficacy and largest therapeutic index for clinical use.

Supported Intellectual PropertyApp/Patent No.Filing DateExpiration Date
Cidofovir Peptide Conjugates as Prodrugs75110517/1/20053/12/26
Phosphonyl Ester Conjugates as Prodrugs80632093/16/200910/13/25
Tyrosine-based Prodrugs of Antiviral Agents89403134/23/20115/27/31
Method to Improve Antiviral Activity of Nucleotide Analogue Drugs14/1148275/7/2012n/a

Prodrug and Drug Delivery Technologies

Unmet Need

Many current and emerging drug therapies suffer from poor PK/PD profiles and poor bioavailability. This can result in a less desirable route of administration, a complicated oral dosing regimen, unwanted side effects, or the complete discontinuation of product development. 


TSRL, Inc. has developed drug delivery technologies to improve dose response, increase solubility, and reduce toxicity associated with extended release drugs. Our extended release formulation provides a PK/PD rational to reduce dose and toxicity of common disease states, including:

  • Cholesterol Synthesis
  • Cardiovascular Disease
  • Asthma Bronchial
  • Peptic Ulcer Disease
  • Gastric Secretion

Rational for improvement in PK/PD:

  • Circadian Rhythm: Night time maximum
  • Reduction of Metabolism: Positional expression of P450 within intestine
  • Formulation: Match maximum activity, delayed release to reduce metabolism, reduce dose and toxicity

Research Status

Below is a list of our technologies that are available for out-licensing or co-development.

Supported Intellectual PropertyApp/Patent No.Filing DateExpiration Date
Controlled Release of Drugs66699541/10/20021/24/2021
Short Peptide Carrier System for Cellular Delivery of Agent717618511/24/20041/10/2025
Methods & Composition of Extended Delivery of Water Insoluble Drugs85357164/1/20054/7/2033
Prodrugs of Neuraminidase Inhibitors918128111/26/201311/26/2033

For more information, contact Business Development at